Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  marimastat
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-12 of 12 for your search:
Start Over
Phase III Randomized Study of Marimastat (a Matrix Metalloproteinase Inhibitor) vs Gemcitabine as First-Line Therapy for Pancreatic Cancer (Summary Last Modified 03/2002)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BB-C03/IVB/128, NCI-V96-0908
Phase III Randomized Study of Marimastat (a Matrix Metalloproteinase Inhibitor) in Glioblastoma Multiforme or Gliosarcoma Following Completion of Conventional First-Line Treatment (Summary Last Modified 06/1999)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BB-C03/IVB/131, NCI-V96-0909
Phase III Randomized, Double Blind, Placebo Controlled Study of Marimastat (a Matrix Metalloproteinase Inhibitor) in Small Cell Lung Cancer Responsive to First Line Chemotherapy (Summary Last Modified 03/2002)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BB-C03/IVB/140, NCI-V96-0910
Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065585, E2196, NCCTG-E2196, NCT00003010
Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: Other
Protocol IDs: BR12, EORTC-08962, CAN-NCIC-BR12, EORTC-08962B, CDR0000065589, NCT00003011
Phase I/II Study of BB-2516 (a Matrix Metalloproteinase Inhibitor) for Advanced Pancreatic Cancer (Summary Last Modified 06/1999)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-95044A1, NCI-V95-0751
Phase I/II Study of Marimastat for Advanced Melanoma (Summary Last Modified 03/2002)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor:
Protocol IDs: CAN-NCIC-IND91, NCI-V95-0757, IND91
Phase II Study of Gamma Knife Radiosurgery and Marimastat (BB-2516) in Patients With Recurrent Malignant Glioma (Summary Last Modified 03/2002)
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: BB-C03-IVB-172, NCI-V96-1112
Phase II Open Label Pilot Study of Adjuvant Marimastat in Patients with Early Stage Breast Cancer (Summary Last Modified 03/2002)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BB-C03/IVB/185, NCI-V97-1265
Phase I Open Label Study of Marimastat Plus Standard Dose Doxorubicin and Cyclophosphamide (AC) in Patients with Stage IV Adenocarcinoma of the Breast (Summary Last Modified 03/2002)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BB-C03/IVB/187, NCI-V97-1266
Start Over